Why Are Top Stocks Up Big Before the Bell Friday? Pre-Market Movers March 20, 2026

Before the opening bell Friday, March 20, 2026, three heavyweight stocks are making massive pre-market moves that could set the tone for the entire trading session. Nvidia (NVDA) is up 6.2% to $187.43 on 8.9M pre-market shares (vs 2.1M average pre-market volume), driven by fresh data on enterprise AI chip adoption. Pharmaceutical giant Regeneron (REGN) is up 4.8% to $892.55 after the FDA granted accelerated approval to its latest immunology drug candidate. Retail giant Target (TGT) jumped 3.1% to $94.27 on better-than-expected Q4 earnings with e-commerce sales up 12% year-over-year. These moves signal strong bullish sentiment heading into the open, but traders need to understand the catalysts driving each move and the key levels to watch.

What's Driving the Biggest Pre-Market Movers Today

Nvidia (NVDA): AI Chip Demand Report Fuels 6.2% Pre-Market Rally

Nvidia's pre-market surge to $187.43 is being powered by a Friday morning report from Gartner showing enterprise data center chip orders are running 18% above consensus forecasts for Q1 2026. The report specifically highlighted Nvidia's H100 and new B100 processors capturing 78% of new AI infrastructure deployments globally, up from 71% last quarter. This validates management's February guidance of 35% data center revenue growth for fiscal 2026. Pre-market volume hit 8.9M shares—already 4.2x the typical pre-market average of 2.1M—signaling institutional conviction ahead of the open.

The move comes just three weeks after Nvidia printed a $190 high on March 1, so traders are watching whether the stock can break and hold above that level when the bell rings. The stock is now up 28% YTD and trading at 42x forward earnings, a premium justified by data center tailwinds but one that leaves little room for disappointment on execution.

Regeneron (REGN): FDA Approval Lifts Stock 4.8% in Pre-Market

Regeneron shares are up 4.8% to $892.55 after the FDA granted accelerated approval to dupilumab for chronic rhinosinusitis, a condition affecting 2.7 million Americans annually. The approval was ahead of the expected June 2026 decision, representing a significant win for the company's immunology pipeline. Peak sales estimates for the drug range from $1.2B to $1.8B annually at full market penetration, representing 2-3% upside to Regeneron's current $61.4B market cap.

Four analysts upgraded Regeneron Friday morning on the approval news. Goldman Sachs raised its price target to $950 (6.5% upside from current levels), while Jefferies lifted its target to $935. The consensus price target across 22 analysts is now $925, up from $878 just yesterday. Pre-market trading volume hit 2.1M shares—2.8x normal pre-market volume of 750K—as institutions repositioned ahead of the open.

Target (TGT): Q4 Earnings Beat Sends Stock Up 3.1% Pre-Market

Retailer Target reported Q4 2025 earnings this morning that crushed expectations. EPS came in at $1.89 versus the $1.72 consensus estimate—a beat of 10%. Revenue hit $38.2B, slightly above the $37.9B expected. The real driver: e-commerce sales surged 12% year-over-year, accelerating from 8.2% in Q3. Same-store sales rose 2.1%, marking the fifth consecutive quarter of comp growth. Gross margin expanded 35 basis points to 28.4%, driven by lower inventory and improved pricing power.

Target shares jumped 3.1% to $94.27 in pre-market action on 3.4M shares—6.2x the typical pre-market volume of 550K. Management guided Q1 2026 same-store sales growth of 1.8-2.2%, suggesting the retailer expects moderating but still-positive momentum through spring. The company is now trading at 18x forward earnings, a reasonable valuation for a retailer with accelerating digital sales and margin expansion. Target stock page shows the stock up 15% YTD as digital strength offsets weakness in physical store traffic.

Pre-Market Volume and Market Breadth

Overall pre-market action Friday morning shows 2,147 stocks advancing versus 891 declining—a 2.4:1 breadth ratio that signals strong bullish sentiment ahead of the open. Total pre-market volume across all stocks hit 187M shares by 8:15 AM, tracking toward the highest pre-market volume since March 12 (when the Fed kept rates steady). This suggests institutional money is actively rotating into the market ahead of the bell, likely on optimism around AI spending and consumer spending resilience.

Key Technical Levels to Watch at the Open

Nvidia (NVDA): $190 Resistance, $182 Support

Nvidia's 50-day moving average sits at $178.92, with the 200-day at $164.31. The stock needs to hold above $190 at the open to confirm a breakout above the March 1 high. If NVDA opens above $190 on strong volume (100M+ shares), the next target is $198, which aligns with the January 2025 breakout level. If the stock opens below $187 and reverses, support is at the $182-$183 zone, where the 50-day MA provides a floor.

Regeneron (REGN): $900 Resistance, $865 Support

Regeneron's 200-day moving average is at $881.45. The stock closed Thursday at $851.89, so the 4.8% pre-market pop to $892.55 suggests institutional buyers see the FDA approval as a catalyst for multiple expansion. Resistance is at $900 (a psychological level and prior breakout zone from February 2026). If REGN holds above $890 at the open on volume above 4M shares, the next target is $920. Support is at $865, where the stock found buyers in mid-March.

Target (TGT): $95 Resistance, $90 Support

Target's 50-day moving average is at $91.32, with the 200-day at $87.15. The pre-market move to $94.27 suggests the stock will test $95 at the open. This is a key level—the highest print since December 2025. If TGT opens above $95 on elevated volume (15M+ shares), the next target is $98. Support is at the $90 level, where the 50-day MA provides a floor.

What Analysts Say About Pre-Market Movers

Nvidia: Seven Buy Ratings on AI Momentum

Across 48 analysts covering Nvidia, the consensus is 38 Buy, 8 Hold, 2 Sell. The average price target is $205, implying 9.4% upside from pre-market levels. Morgan Stanley maintained its Overweight rating with a $220 target, noting the Gartner data confirms Nvidia's durable competitive moat in AI chips. However, Bank of America downgraded the stock to Neutral this week, citing valuation concerns at 42x forward earnings, though BofA kept a $200 price target that allows for modest upside.

Regeneron: Four Upgrades on FDA Approval

Goldman Sachs (Neutral → Buy), Jefferies (Hold → Buy), and Piper Sandler (Buy → Overweight) upgraded Regeneron Friday morning following the FDA approval. Evercore ISI maintained its Outperform rating and raised its target to $940. The consensus rating is now 28 Buy, 12 Hold, 1 Sell. Average price target is $925, implying 3.7% upside from current pre-market levels. The bull case hinges on the drug reaching peak sales of $1.5B+ and gross margin expansion from higher-margin immunology products.

Target: Mixed Reactions on Margin Pressure Concerns

Consensus on Target is 24 Buy, 18 Hold, 4 Sell. The average price target is $98, implying 4% upside. Barclays upgraded Target to Overweight Friday morning on the e-commerce acceleration and margin expansion, raising its target to $105. However, Citi maintained its Sell rating, arguing that same-store sales growth of 1.8-2.2% for Q1 2026 signals decelerating momentum and warns of margin pressure from promotional activity later in the year.

What's Next for These Pre-Market Movers

Nvidia: Data Center Demand Report Becomes the New Playbook

The next catalyst for Nvidia is the company's Q4 FY2026 earnings call on May 28, 2026, where management will provide guidance on H200 GPU ramp and B100 adoption. Traders are pricing in a 7-9% move on the earnings date. In the near term, any pullback below $182 should attract buyers given the strong Gartner report and Fed interest rate stability. Bull case: Nvidia reaches $220 by end of Q2 on sustained data center strength. Bear case: AI spending growth disappoints in Q2, stock sells off to $170 on valuation concerns.

Regeneron: Drug Launch Timeline Becomes Key Watch

The key catalyst for Regeneron is Q1 2026 earnings on May 1, when management will outline the commercial launch strategy for the newly approved dupilumab indication. Analysts expect guidance on peak sales contribution for FY2026. If the company projects $300M+ in first-year sales from the new indication, the stock could rally to $950+. Bull case: Peak sales reach $1.5B+ by 2029, driving $180B+ market cap. Bear case: Launch execution stumbles, stock retreats to $850 on disappointment.

Target: Q1 2026 Earnings the Execution Test

Target reports Q1 2026 earnings on May 15, 2026. This is the critical test for whether the company can sustain e-commerce growth and margin expansion into spring. Management's guidance of 1.8-2.2% same-store sales growth for Q1 appears achievable but leaves little margin for error. If Target beats Q1 and raises FY2026 EPS guidance, the stock could rally to $105+. If same-store sales decelerate and management cites consumer weakness, expect a selloff toward $85. Check the earnings calendar for exact dates.

Frequently Asked Questions

Why is Nvidia stock up today, March 20, 2026?

Nvidia rose 6.2% pre-market to $187.43 after Gartner reported enterprise AI chip orders are 18% above forecasts and Nvidia holds 78% market share for new deployments. The report validates the company's data center growth guidance.

Why is Regeneron stock up today?

Regeneron jumped 4.8% to $892.55 after the FDA granted accelerated approval to dupilumab for chronic rhinosinusitis, ahead of the expected June decision. Analysts raised price targets to $925-$950 on peak sales estimates of $1.2B-$1.8B annually.

Why is Target stock up today?

Target rose 3.1% to $94.27 after reporting Q4 2025 EPS of $1.89 versus $1.72 expected and e-commerce sales growth of 12% YoY. Gross margin also expanded 35 basis points, signaling pricing power and operational efficiency.

What's the analyst consensus price target for Nvidia?

The average price target across 48 analysts is $205, implying 9.4% upside. 38 analysts rate NVDA Buy, 8 Hold, and 2 Sell. Goldman Sachs has the highest target at $220.

Is Target stock a good value at current levels?

Target trades at 18x forward earnings, a reasonable valuation given accelerating e-commerce sales (+12% YoY) and margin expansion. Analyst consensus is 24 Buy, 18 Hold, with an average price target of $98, suggesting 4% upside. This frames the risk-reward as balanced for patient investors.

What should traders watch when the market opens?

Watch whether Nvidia can hold $190 resistance on volume above 100M shares (indicating institutional buying). For Regeneron, watch for $900 resistance on volume above 4M shares. For Target, watch $95 resistance on volume above 15M shares. Any breaks above these levels with high volume suggest strong conviction and could fuel continued rallies. For more on reading stock charts and volume, see our guide.